DISCOUNT-ZERTIFIKAT - ASTRAZENECA | Market Closed - Boerse Frankfurt Warrants 20:36:56 07/06/2024 BST | ||
| 88.93 EUR | 0.00% |
|
| Current month | +0.15% | ||
| 1 month | +0.49% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 07/06/24 | 88.93 | 0.00% |
| 06/06/24 | 88.93 | +0.07% |
| 05/06/24 | 88.87 | 0.00% |
| 04/06/24 | 88.87 | +0.07% |
| 03/06/24 | 88.81 | +0.01% |
Real-time Boerse Frankfurt Warrants
Last update June 07, 2024 at 08:36 pm
More quotesStatic data
| Product type | Certificati Discount |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
Société Générale
|
| WKN | SU229D |
| ISIN | DE000SU229D4 |
| Date issued | 01/12/2023 |
| Maturity | 20/09/2024 (103 Days) |
| Parity | 1 : 1 |
| Emission price | 84.59 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 88.98 € |
|---|---|
| Lowest since issue | 84.63 € |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
159.8
USD
Average target price
173.1
USD
Spread / Average Target
+8.38%
- Stock Market
- Certificates
- Certificat
